Cellectar Biosciences (CLRB) Gains from Investment Securities (2022 - 2026)
Cellectar Biosciences (CLRB) posted Gains from Investment Securities of -$297833.0 for Q4 2025, down 1.21% sequentially from -$294276.0 in Q3 2025, and up 97.08% YoY from -$151120.4 in Q4 2024.
Cellectar Biosciences (CLRB) Gains from Investment Securities (2022 - 2026) Analysis & Trends
Cellectar Biosciences has reported Gains from Investment Securities for 4 years, with the latest figure at -$297833.0 in Q4 2025.
- Quarterly Gains from Investment Securities rose 97.08% year-over-year to -$297833.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$753707.0 (up 94.54% YoY) and the FY2025 annual result came in at -$753707.0, up 94.54% from the prior year.
- Gains from Investment Securities retreated to -$297833.0 in Q4 2025 per CLRB's latest filing, from -$294276.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $15.0 million in Q1 2024 and troughed at -$12.5 million in Q2 2024.
- A 4-year average of -$899657.3 and a median of -$400799.0 in 2022 frame the typical range for Gains from Investment Securities.
- The widest YoY moves for Gains from Investment Securities: up 2662.68% in 2023, down 1490.8% in 2023.
- Over 4 years, Gains from Investment Securities stood at -$1.6 million in 2022, then sank by 173.54% to -$4.5 million in 2023, then tumbled by 128.57% to -$10.2 million in 2024, then surged by 97.08% to -$297833.0 in 2025.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered -$297833.0, -$294276.0, and -$501598.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cellectar Biosciences | 6.73 Mn | 6.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -132,000.00 |
| Jun 30, 2026 | -132,000.00 |
| Dec 31, 2025 | -297,833.00 |
| Dec 31, 2025 | -297,833.00 |
| Sep 30, 2025 | -294,276.00 |
| Sep 30, 2025 | -294,276.00 |
| Jun 30, 2025 | -501,598.00 |
| Jun 30, 2025 | -501,598.00 |
| Mar 31, 2025 | 340,000.00 |
| Mar 31, 2025 | 340,000.00 |
| Dec 31, 2024 | -10.21 Mn |
| Dec 31, 2024 | -10.21 Mn |
| Sep 30, 2024 | -6.09 Mn |
| Sep 30, 2024 | -6.09 Mn |
| Jun 30, 2024 | -12.46 Mn |
| Jun 30, 2024 | -12.46 Mn |
| Mar 31, 2024 | 14.96 Mn |
| Mar 31, 2024 | 14.96 Mn |
| Dec 31, 2023 | -4.47 Mn |
| Dec 31, 2023 | -4.47 Mn |